1. Scrip
  2. >>Therapy Areas
  3. >>Alimentary/Metabolic

Veru Hopes To Improve The QUALITY Of Drug-Induced Weight Loss

 
• By Alaric DeArment

The biotech announced results of the Phase IIb QUALITY trial of enobosarm in older patients taking Wegovy, showing reduced loss of lean mass.

Image of semaglutide, liraglutide injections
(Shutterstock)

Although GLP-1 agonists for obesity have made a significant difference for patients and brought in a financial windfall for their manufacturers, there remains a lingering problem of the drugs reducing not only fatty tissue but muscle as well, a potentially serious problem for elderly people. Veru has positive data for enobosarm, which it hopes can remedy the issue and potentially continue to promote weight loss even after patients discontinue GLP-1 agonist therapy.

The Miami-based company announced on 27 January topline results from the Phase IIb QUALITY trial testing Novo Nordisk’s Wegovy (semaglutide) plus enobosarm against Wegovy alone among overweight or obese patients...

Key Takeaways
  • Veru said the Phase IIb QUALITY trial met its primary endpoint of preserving total lean body mass in patients receiving enobosarm with Wegovy versus placebo.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Alimentary/Metabolic

More from Scrip

Zydus To Continue Mirabegron Sales, Looks To World-First Dual Shigella-Typhoid Vaccine

 
• By Vibha Ravi

Zydus expects strong mirabegron sales in FY26 amid US litigation even as it builds a growth pillar in vaccines with a world-first, Gates Foundation-aided dual shigella-typhoid vaccine under development and others on the WHO prequalified list

Challenging Environment For Biopharma Is A Tailwind For Royalty Pharma

 
• By Jessica Merrill

The royalty revenue stream acquirer has around 40 products in its portfolio and expects to generate roughly $3bn this year. Head of R&D and investments Marshall Urist talked about the investment strategy at the RBC Healthcare Conference.

Finance Watch: SV Closes Second Dementia Discovery Fund, Exceeding $250m Goal

 
• By Mandy Jackson

Private Company Edition: SV Health Investors revealed the final closing of its second Dementia Discovery Fund. Also, Eikon cut nearly 15% of its staff, Pathos AI raised $365m in series D venture capital and CellCentric completed a $120m series C round, among other financings.